Li Xiantao

Aniphe BioLab Inc., established in 2018, is committed to becoming an internationally renowned preclinical pharmacodynamic evaluation company in the new era of biopharmaceutical development. The company has built a comprehensive SPF‑grade laboratory animal center that integrates both animal production and experimental services.
Aniphe BioLab focuses on the fields of laboratory animals and animal‑based research services, offering a comprehensive portfolio that includes contract breeding and husbandry, strain preservation and pathogen clearance for genetically edited models, the generation of human disease models, and pharmacological and toxicological testing services—covering multiple research areas such as oncology, neuroscience, and metabolism. Backed by a highly skilled technical team and an extensive animal resource base, Aniphe BioLab provides a wide array of disease‑specific animal models, including mouse and rat models of cerebral ischemia–reperfusion (MACO/R), myocardial infarction/ischemia (MI), thoracic aortic constriction (TAC), patient‑derived xenograft (PDX) tumor models, cell‑line‑derived xenograft (CDX) tumor models, spinal cord injury (SCI) models, epilepsy models, and Alzheimer’s disease (AD) models. The company also offers tailored pharmacological and efficacy evaluation services for these disease models. In collaboration with Zhengzhou University and East China Normal University, Aniphe BioLab has established standardized methodologies and workflows for gene editing in mice and rats, gene editing and cloning in miniature pigs, and the creation of surgical and inducible disease models. Furthermore, it maintains a complete suite of small‑animal behavioral assessment systems and mouse imaging platforms, ensuring the smooth execution of preclinical drug‑efficacy studies.
Aniphe BioLab has established a comprehensive R&D, manufacturing, and sales process and management system. Guided by market demand and committed to the principles of pragmatism, truth-seeking, and mutual benefit, the company fosters innovation through industry–university–research collaboration, serving the fields of biological research and the new‑drug development industry, thereby contributing to human health and well-being.